AstraZeneca required a digital solution to support medication and lifestyle management for patients suffering from chronic obstructive pulmonary disease (COPD). The company needed a program with personalized self-management tools that respond to the individual’s needs in the right way, at the right time.
AstraZeneca collaborated with Clario to develop a digital health program called “Me&My COPD™”, which is implemented through Care Commissioning Groups (CCGs) in the UK healthcare system. Patient interaction is primarily via an app that captures daily diary and PEF readings via a Bluetooth® spirometer. Personalized goals and regular readings from a clinically-validated questionnaire are also tracked. The program is supported by a web portal which provides additional information relevant to each patient’s progress.
Patients can better manage their condition with tailored care pathways
and health tools, including:
Web Portal provides additional information relevant to each patient’s progress
Personalized goals tracked and coaching provided through digital program
Patients using Me&My COPD can collect, transmit and review their own clinical data in real-time. Additionally, they are able to benefit from improved medication and lifestyle management with care pathways, personalized coaching as well as goal management tools, individually tailored to their needs. The success of the program has led to a streamlined version now being rolled out globally in support of AstraZeneca’s brand.